BSE filing, NSE: ARCIL. Summary written from the filing by ALFA Finder's alert engine.
Asset Reconstruction Company (India) Ltd: key numbers
- Share price
- ₹124.05
- Market cap
- ₹4,030 Cr
- Revenue (annual)
- ₹753.0 Cr
- Net profit (annual)
- ₹407.8 Cr
- Promoter holding
- 77.45%
- FII holding
- 6.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Asset Reconstruction Company (India) Ltd
All →Asset Reconstruction Company (India) Results Update
ARCIL's H1FY27 release shows total income up 48% to Rs.516.4 crore and PAT up 54% to Rs.290.0 crore. Investors should view performance over a longer horizon.
Asset Reconstruction Company (India) Management Change
ARCIL re-appointed Balachander Rajaraman as independent director for 36 months and appointed Sanjay Vasarkar as senior management personnel. Deloitte was also re-appointed as internal auditor.
- Execution
- 36 months (director re-appointment term)
Asset Reconstruction Company (India) Q2 FY27 Results: Net Profit ₹157.8 Cr, Up 55.8% YoY
Asset Reconstruction Company (India) Ltd reported revenue from operations of ₹276.5 Cr (+30.7% YoY) and net profit of ₹157.8 Cr (+55.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹157.8 Cr · +55.8% YoY
Asset Reconstruction Company (India) Board Meeting Date
ARCIL will hold a board meeting on 29 October 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window is closed from 1 October to 1 November 2026.
Asset Reconstruction Company (India) Other Announcement
Asset Reconstruction Company (India) Ltd filed its quarterly shareholding pattern as mandated under SEBI regulations. This routine disclosure details the company's current shareholder structure.
Asset Reconstruction Company (India) Earnings Call Transcript: Key Takeaways
ARCIL reported a 107% PAT jump in Q1 FY27, driven by chunky corporate resolutions despite seasonal lulls in asset acquisitions. Management is pivoting towards retail and MSME segments while leveraging technology for collections.
Other other announcement announcements
All →Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Vineet Laboratories Other Announcement
Vineet Laboratories' board appointed SVRL & Co. as statutory auditors, subject to shareholder approval. The five-year term runs from the 10th AGM to the 16th AGM.
Physicswallah Other Announcement
Physicswallah's IPO monitoring report flags a deviation from offer objects for the quarter ended September 30, 2026. The diverted funds were restored on October 30, 2026.
Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
PDS Other Announcement
PDS Limited submitted the CRISIL Ratings monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation in the utilisation of its QIP proceeds.
Schaeffler India Other Announcement
Schaeffler India disclosed that CRISIL ESG Ratings assigned it an ESG Score of 67 on an unsolicited basis. The company did not engage or subscribe to the rating provider.